logo

Kodiak Sciences Inc. (KOD)



Trade KOD now with
  Date
  Headline
8/8/2022 6:31:29 AM Kodiak Sciences Reports Positive Topline Results From BEACON Phase 3 Study In Retinal Vein Occlusion
5/10/2022 4:53:33 PM Kodiak Sciences Q1 Loss Per Share Of $1.83 Vs. Loss Per Share Of $0.98 Last Year
2/23/2022 6:03:39 AM Kodiak Sciences Says Phase 2b/3 Study Of KSI-301 Fails To Meet The Primary Endpoint
2/3/2022 5:37:39 AM Kodiak Sciences Completes Enrollment In GLEAM And GLIMMER Phase 3 Trials Of KSI-301 In Diabetic Macular Edema
12/16/2021 5:33:06 AM Kodiak Sciences Completes Enrollment In BEACON Phase 3 Clinical Trial Of KSI-301 In Retinal Vein Occlusion
9/1/2021 5:53:38 AM Kodiak Sciences Announces New Seven-year Performance Stock Option Awards
8/9/2021 4:02:51 PM Kodiak Sciences Q2 Loss/share $1.08 Vs. Loss $0.58 Year Ago
3/1/2021 5:31:43 AM Kodiak Sciences Q4 Net Loss $46.6 Mln Or $0.97/Shr Vs Loss Of $15.6 Mln Or $0.40/Shr Last Year